A Simple Key For BCAT-IN-4 Unveiled
MI-CP151 was a phase 1b randomised, double-blind, placebo managed, dose-escalation, multicentre study To guage a number of intravenous doses of sifalimumab, in Grownup individuals with dermatomyositis or polymyositis (NCT00533091). Most important demo targets ended up to evaluate the safety and tolerability of sifalimumab in dermatomyositis or poly